Bioventus Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 7% revenue growth, 24% higher adjusted EBITDA, and record cash flow, driven by strong execution and investments in key growth drivers. Full-year guidance for adjusted EPS and cash from operations was raised, with accelerating growth expected in the second half.
-
Significant transformation has led to above-market growth, high margins, and strong cash flow. Four growth drivers—ultrasonics, international, PNS, and PRP—are set to accelerate future performance, with disciplined investment and a focus on debt reduction.
Fiscal Year 2025
-
Delivered 10% organic revenue growth in Q4 2025, with record cash flow and margin expansion. 2026 guidance targets $600–$610 million in sales, EPS of $0.73–$0.77, and continued investment in growth drivers like PNS, PRP, and Ultrasonics.
-
The presentation highlighted strong above-market growth, peer-leading margins, and a robust innovation pipeline across core, expansion, and emerging segments. Cash flow and leverage improvements are enabling greater capital flexibility, supporting the goal of reaching $1 billion in revenue.
-
Q3 saw 8% organic revenue growth, margin expansion, and strong cash flow, with all segments contributing and new product launches gaining traction. 2025 guidance was reaffirmed, and debt reduction remains on track, positioning for continued profitable growth.
-
A diversified medical device company has executed a successful turnaround, focusing on high-margin growth in pain, surgical, and restorative therapies. Key drivers include ultrasonics, HA, and new PRP and PNS launches, with disciplined investment and a focus on debt reduction.
-
The company is driving above-market growth across pain, surgical, and restorative therapies, with strong financial discipline leading to improved margins, cash flow, and reduced leverage. Emerging businesses in PNS and PRP, along with international expansion, are set to accelerate growth from 2026.
-
Q2 2025 saw 6% organic growth, strong profitability, and robust cash flow, with FDA clearance for new PNS products opening a $2B market opportunity. Full-year guidance was reaffirmed despite $5M in FX and tariff headwinds, and refinancing improved liquidity and reduced interest costs.
-
Q1 organic revenue grew 5% to $124M, with adjusted EPS up 33% to $0.08. Full-year guidance for 6%-8% organic growth, $112-$116M adjusted EBITDA, and $0.64-$0.68 EPS was reaffirmed, with second-half acceleration expected.
-
Streamlined portfolio and operational focus drove strong 2024 growth, margin expansion, and debt reduction. High-growth assets and disciplined execution set the stage for doubling free cash flow and further margin gains in 2025, with long-term growth from innovation and improved capital structure.
Fiscal Year 2024
-
Delivered double-digit organic revenue growth and strong margin expansion in 2024, with Q4 revenue up 14% and Adjusted EBITDA up 28% year-over-year. 2025 guidance calls for 6–8% organic growth, further margin improvement, and leverage below 2.5x.
-
Q3 revenue grew 15% year-over-year, with double-digit gains in all major segments and improved profitability. Full-year guidance was raised, and the company expects continued margin expansion, strong cash flow, and lower leverage into 2025.
-
Leadership restructuring and portfolio focus have driven strong financial recovery, with double-digit growth in pain treatments and surgical solutions. Divestiture of lower-margin assets and operational improvements are expected to further enhance margins and growth.
-
Double-digit organic revenue growth and margin expansion drove a strong Q2, with raised full-year guidance for sales, EBITDA, and EPS. Strategic divestiture and investments in R&D and commercial execution are expected to fuel continued growth and improved liquidity.